During the Phase 1, 1d3a carried out in parallel a study of the technical feasibility of the project together with its economic viability, thanks to a Business Plan. The technical feasibility mainly deals with a study of the technical added value of MED1C paying special attention to three key elements: potential competitors of MED1C solution; the main differentiation factors of MED1C compared to its competitors and main technologies used in existing systems. This initial analysis has been crucial for the definition of the Work Plan of Phase 2 project and for the identification of potential weaknesses of the current application. In total, nine competitors have been identified worldwide but none of these solutions offers, in a single device, the range of the services proposed by MED1C (Video TAGGING, Video Edition, Medical History, Recording on real-time signals & data information, standardisation, etc.). During this 4-month period, the 6 pilots of phase 2 have been identified and confirmed their participation in the project. These pilots are located in Spain, Denmark, Italy and Greece. MED1C has also received the support of several hospitals all over Europe which signed a Letter of Support to the project.
Concerning the business plan, according to our estimations, our solution is totally viable and we expect a return on investments in 3rd year, that is to say one year after the Phase 2 project’s end. Regarding the potential market, with more than 1.7 million of doctors as potential MED1C users, the European health sector is a high volume market, which is already mature. The use of innovative ICT solutions in this sector, specially the application of video capture and analysis technologies, is growing over the last years. MED1C will address first the EU health community at first to solve the need of a simple, cost-effective and efficient solution. After its successful implementation in the EU market, 1D3A will target the health sector globally. In regards of our expected sales, they will be multiplied by 3 in year 3 (150 units) and then by 2.3 in year 4 (350 units) compared to the objectives fixed for Phase-2 project (50). The commercialisation strategy, especially in Europe, will be facilitated thanks to the collaboration with the 6 hospital-pilots which will give us a direct access to their local markets, at least 4 during the project implementation. All these figures and the final commercialisation strategy will be confirmed during the Phase-2 project which is expected to last 2 years.
